This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Synta Is Run-Up to ASCO Lung Cancer Data

Stocks in this article: SNTA HSP

LEXINGTON, Calif ( TheStreet) -- Biotech run-up traders should be looking at a potentially valuable clinical trial catalyst with Synta Pharmaceuticals (SNTA) .

Synta is scheduled to present updated results from phase II (GALAXY-1) portion of its ganetespib lung cancer study on June 3rd at the American Society of Clinical Oncology (ASCO) annual meeting. Most the ASCO research abstracts are slated to be released on Wednesday, however, the Synta data have been classified as a "late breaker" and are therefore embargoed until the actual day of presentation.

The lung cancer market is worth billions of dollars in annual sales, so investors will be eyeing the gantespib data closely. Synta's market valuation of $500 million doesn't price in the overall ganetespib market opportunity, especially if the drug's use can be expanded beyond lung cancer into other tumor types.

Synta has a decent balance sheet for a small-cap biotech. As of March 31, Synta has $90.4M in cash, sufficient to fund planned operations into the second quarter of 2014. The company's outstanding share count totals 69 million and it carries $23.6M in total debt.

Shares of Synta were trading close to $11 as recently as May 1, before taking a huge hit and dropping down to a low of $6.60 on the surprise resignation of R&D Chief Dr. Sumant Ramachandra. Investors and traders looked at this resignation as a bad sign, ahead of the expected ASCO data presentation.

I believe investors overreacted to Ramachandra's resignation, especially considering he only worked at Synta for six weeks and was commuting long distance from Chicago to the company's headquarters outside Boston. Ramachandra cited personal reasons for leaving the company and on Tuesday, he rejoined his former employer, Hospira (HSP), headquartered in Chicago, as its chief scientific officer.

So, it seems like Ramachandra really did leave Synta only for personal reasons stemming from his long commute. That means the dip in Synta's stock price created a great buying opportunity for run-up traders heading into the June 3 presentation of the ganetespib data at ASCO.

If Synta shares simply recover back the level before Ramachandra's resignation was announced, it would represent a nearly 30% gain over current share price. The market, at times, has a very short memory and I feel that Synta has a very good chance to recover back to $10 within the next few weeks. As always, run-up traders should exit their positions before the ganetespib data are released on June 3.

Messier is long Synta.

Mark Messier is the founder of BioRunUp.com. Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profit in just 4 years. In April 2010, Messier founded the subscription-based stock-trading web site BioRunUp.com to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,803.16 +25.01 0.14%
S&P 500 2,067.75 +6.52 0.32%
NASDAQ 4,757.5990 +9.2030 0.19%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs